These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 10477679

  • 1. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 2. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.
    Blood; 2002 Jan 01; 99(1):10-4. PubMed ID: 11756146
    [Abstract] [Full Text] [Related]

  • 3. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.
    Blood; 2004 Mar 15; 103(6):2039-45. PubMed ID: 14630791
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 15; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE, REACH Investigators.
    Lancet Haematol; 2024 Jun 15; 11(6):e425-e435. PubMed ID: 38701812
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.
    Pediatrics; 2008 Dec 15; 122(6):1332-42. PubMed ID: 19047254
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U, Adebayo I, Erigbuem I, James E, Kumode E, Nnodu O, Adekile A.
    Pediatr Blood Cancer; 2021 Jun 15; 68(6):e28969. PubMed ID: 33788390
    [Abstract] [Full Text] [Related]

  • 8. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 9. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, Al-Lamki Z, Wali Y.
    Eur J Haematol; 2013 Jun 25; 90(6):519-24. PubMed ID: 23489171
    [Abstract] [Full Text] [Related]

  • 10. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul 25; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyurea in children: present and future.
    Vichinsky EP.
    Semin Hematol; 1997 Jul 25; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [Abstract] [Full Text] [Related]

  • 12. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 13. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE, BABY HUG Investigators.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):170-2. PubMed ID: 21744485
    [Abstract] [Full Text] [Related]

  • 14. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE.
    Am J Hematol; 2016 Feb 15; 91(2):238-42. PubMed ID: 26615793
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC.
    Hemoglobin; 2012 Feb 15; 36(5):409-20. PubMed ID: 22881992
    [Abstract] [Full Text] [Related]

  • 18. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
    Ware RE, Zimmerman SA, Schultz WH.
    Blood; 1999 Nov 01; 94(9):3022-6. PubMed ID: 10556185
    [Abstract] [Full Text] [Related]

  • 19. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Nov 01; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.